A18.32 Tuberculous enteritis

Name of the Condition

• Tuberculous enteritis
• ICD Code: A18.32

Summary

Tuberculous enteritis is a form of extrapulmonary tuberculosis where Mycobacterium tuberculosis infects the small or large intestine. This condition typically results from the spread of TB bacteria from a primary site, usually the lungs, via the bloodstream or lymphatic system. It can involve inflammation of the intestinal mucosa, leading to localized or systemic symptoms.

Causes

Tuberculous enteritis is caused by the dissemination of Mycobacterium tuberculosis from an existing infection, most commonly pulmonary tuberculosis. The bacteria may travel to the intestinal tract during active disease or reactivation of latent TB. Direct ingestion of infected material is rare but possible in certain cases.

Risk Factors

• Immunocompromised states, such as HIV/AIDS or chronic immunosuppressive therapy.
• History of untreated or inadequately treated tuberculosis.
• Close contact with individuals who have active TB.
• Living in or traveling to regions with high TB prevalence.
• Underlying conditions like diabetes, malnutrition, or chronic kidney disease.

Symptoms

• Abdominal pain or cramping.
• Diarrhea or constipation.
• Fever, chills, or night sweats.
• Nausea, vomiting, or loss of appetite.
• Unintentional weight loss.
• Blood in stool (hematochezia) or mucus in stool.

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging, and laboratory tests. A thorough patient history, including TB exposure or prior infection, is essential. Imaging studies like CT scans or endoscopy may reveal intestinal abnormalities. Laboratory tests include stool analysis, blood tests for inflammation, and microbiological confirmation via culture or nucleic acid amplification tests (NAAT) from tissue or fluid samples. Biopsy of affected intestinal tissue may be performed to identify granulomas or acid-fast bacilli.

Treatment Options

Treatment follows standard antitubercular therapy, typically a multi-drug regimen (e.g., isoniazid, rifampin, pyrazinamide, and ethambutol) for 6–9 months. Adjunctive therapies, such as corticosteroids, may be used for severe inflammation. Nutritional support and management of complications (e.g., bowel obstruction) are also important. Treatment duration and drug selection depend on drug susceptibility and patient factors.

Prognosis and Follow-Up

Prognosis is generally favorable with early diagnosis and appropriate treatment, though it varies based on the extent of intestinal damage and patient comorbidities. Follow-up includes monitoring for treatment response, adverse drug effects, and recurrence. Regular clinical assessments and repeat imaging or endoscopy may be needed to evaluate healing.

Complications

• Intestinal obstruction or perforation.
• Malabsorption or malnutrition.
• Fistula formation (abnormal connections between intestines or other organs).
• Sepsis or systemic infection.
• Chronic abdominal pain or functional bowel disorders.

Lifestyle & Prevention

• Complete the full course of prescribed antitubercular therapy to prevent recurrence.
• Maintain good nutrition and hydration to support healing.
• Practice good hygiene, especially handwashing, to reduce infection risk.
• Avoid close contact with individuals who have active TB until they are no longer contagious.
• Screen for and manage underlying conditions that increase TB susceptibility (e.g., HIV, diabetes).

When to Seek Professional Help

Seek immediate medical attention if you experience:

• Severe abdominal pain, vomiting, or inability to tolerate fluids.
• Signs of intestinal perforation (e.g., fever, rigid abdomen, shock).
• Persistent or worsening symptoms despite treatment.
• Unexplained weight loss, night sweats, or persistent fever.

Tips for Medical Coders

Code A18.32 is specific to tuberculous enteritis, a subset of intestinal tuberculosis. Documentation should clearly indicate the affected intestinal segment (e.g., small or large intestine) and confirm the diagnosis via clinical, radiological, or microbiological findings. Ensure the code aligns with the primary diagnosis and that supporting documentation (e.g., biopsy results, imaging reports) is available to validate the code assignment. Avoid using this code for peritoneal or mesenteric gland involvement, which are coded separately.